BAT CEO Denies Moving Listing to New York

BAT by 2FIRSTS.ai
Mar.18.2024
BAT CEO Denies Moving Listing to New York
British American Tobacco CEO Tadeu Marroco denies plans to move the company's listing from London to New York.

According to a report from the UK's Financial Times, Tadeu Marroco, the CEO of British American Tobacco, has denied the idea of moving the company's listing from London to New York, calling it a "distraction." Previously, the top ten shareholders who were pushing for this change have sold their stakes in the tobacco company.

 

Maroko told the Financial Times that the change of listing venue "will cause a lot of disruption internally," and he is "uncertain if its benefits are as obvious as some people suggest.

 

Last year, Rajiv Jain, Chairman and Chief Investment Officer of the US investment group GQG Partners with $105 billion in assets, urged British American Tobacco to switch its primary listing and clashed with management over the decision to suspend the company's stock buyback program.

 

According to two sources familiar with the matter, GQG sold its 4% stake in British American Tobacco last July because they refused to move and leverage the larger pool of capital in the US, particularly in tobacco stocks. In Europe, an investment environment dominated by ESG considerations means that almost no capital is willing to invest in the tobacco industry.

 

When asked whether he would consider changing the listing location during his tenure, Maroko said, "I believe we should not focus on this issue during this period.

 

He added that there are "many other things" he needs to do, including income in the United States and new products. "There is no indication that... going to the United States is a certainty."

 

He acknowledged that the London capital market is working hard to attract and retain listed companies, but he mentioned the advantages of staying in the UK for investors. Companies that have already moved their main listing venues to the United States include building materials group CRH, packaging company Smurfit Kappa, and gambling group Flutter.

 

Marroco stated, "If you hold shares in a British (listed) company and are overseas, you do not have to pay withholding tax on dividends, unlike in the United States."

 

He said, "I hope that within 10 years, we no longer have to have these discussions." "The reason why there is such a high level of emotions today is due to the frustration caused by some people leaving."

 

For investors, the main reason they are attracted to invest in tobacco stocks is the capital return from dividends and stock buybacks. One of the biggest active investors in British American Tobacco is Spring Mountain Investments, which is an investment vehicle of Kenneth Dart, a billionaire from the Cayman Islands and one of the world's largest foam cup manufacturers.

 

British American Tobacco announced this month that it will use the proceeds from the sale of a portion of its shares in Indian conglomerate ITC for £1.7 billion to restart its stock buyback program, starting with a £700 million buyback this year.

 

Marroco stated, "For me, the most important thing is the restart of repurchases, which should be a consistent feature of our capital allocation."

 

British American Tobacco is facing challenges in reversing the decline in tobacco sales in the United States, its largest market. This is due to people turning to cheaper brands and alternative tobacco products, in which the company is lagging behind the highly successful PMI, whose IQOS heated tobacco product has been very successful.

 

British American Tobacco's goal is to have 50% of its revenue come from alternative products by 2035, such as its Vuse e-cigarette and Glo heated tobacco devices.

 

Marroco acknowledged that English-American Tobacco "started late in the heated tobacco products field," but he stated that due to the company's market share in the US, they have the ability to catch up. "We have a large business in the US that can be used to sell (new products)."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former FDA Scientist Questions ZYN Review Over Pouch Material and Microplastic Risk
Former FDA Scientist Questions ZYN Review Over Pouch Material and Microplastic Risk
A former FDA toxicologist has questioned whether the agency fully assessed the material used in ZYN nicotine pouches before authorizing them for sale, raising concerns over possible microplastic exposure, according to STAT and The Examination.
Jul.16
BAT New Categories Revenue Rises 18% in H1 2026 as Broad Portfolio Offers More Ways to Win—and Lose
BAT New Categories Revenue Rises 18% in H1 2026 as Broad Portfolio Offers More Ways to Win—and Lose
British American Tobacco’s New Category revenue rose 18% at constant rates in the first half of 2026. Nicotine-pouch brand Velo expanded rapidly, while Vuse recovered as U.S. enforcement against illicit e-vapor products strengthened. Heated-tobacco platform glo remained under pressure, and cigarettes continued to provide most of the group’s profit and cash. Compared with PMI and JT, BAT has more routes to growth—but also greater regulatory, investment and execution risks across its broader portfolio.
BAT
Jul.30
Changing Assumptions in U.S. Cigar Consumption: 2Firsts Interviews Cigar Educator Mechelle Merkerson
Changing Assumptions in U.S. Cigar Consumption: 2Firsts Interviews Cigar Educator Mechelle Merkerson
U.S. premium cigar culture is shifting toward education, broader choice and deeper links to craftsmanship and origin, cigar educator Mechelle Merkerson told 2Firsts. She sees boutique brands, women consumers and production-region experiences making knowledge central to cigar participation. For global brands, retailers and emerging markets such as China, education may help turn curiosity into sustained engagement.
Special Report
Jul.06
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Argentina Updates Health Warning Rules to Include Vapes and Nicotine Pouches
Argentina Updates Health Warning Rules to Include Vapes and Nicotine Pouches
Argentina’s Ministry of Health has updated its health warning rules for tobacco and nicotine products, adding e-cigarettes, vapes, heated tobacco products, sticks and nicotine pouches to mandatory warning requirements.
Jul.08
Italian Court Ends Six-Year Cigarette Excise Dispute, Rejecting Damages Claim
Italian Court Ends Six-Year Cigarette Excise Dispute, Rejecting Damages Claim
Italy’s Lazio Regional Administrative Court has dismissed an appeal by Italian Tobacco Manufacturing and Manifattura Italiana Tabacco over the cigarette excise calculation mechanism, upholding the minimum tax burden rules and excluding compensation for smaller tobacco operators.
News
Jun.26 by 2Firsts Perspectives